Expression of 11beta-hydroxysteroid dehydrogenase 2 contributes to glucocorticoid resistance in lymphoblastic leukemia cells

Shuji Sai; Yuichi Nakagawa; Rie Yamaguchi; Masako Suzuki; Kimiyoshi Sakaguchi; Shuichi Okada; Jonathan R. Seckl; Takehiko Ohzeki; Karen E. Chapman

doi:10.1016/j.leukres.2011.07.002

Expression of 11beta-hydroxysteroid dehydrogenase 2 contributes to glucocorticoid resistance in lymphoblastic leukemia cells

Shuji Sai, Yuichi Nakagawa, Rie Yamaguchi, Masako Suzuki, Kimiyoshi Sakaguchi, Shuichi Okada, Jonathan R. Seckl, Takehiko Ohzeki, Karen E. Chapman

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

Abstract

Synthetic glucocorticoids (GCs) form a crucial first-line treatment for childhood acute lymphoblastic leukemia (ALL). However prolonged GC therapy frequently leads to GC-resistance with an unclear molecular mechanism. 11β-hydroxysteroid dehydrogenase (11β-HSD) 2 inactivates GCs within cells. Here, we show the association between GC sensitivity and 11β-HSD2 expression in human T-cell leukemic cell lines. 11β-HSD2 mRNA and protein levels were considerably higher in GC-resistant MOLT4F cells than in GC-sensitive CCRF-CEM cells. The 11β-HSD inhibitor, carbenoxolone pre-treatment resulted in greater cell death with prednisolone assessed by methyl-thiazol-tetrazolium assay and caspase-3/7 assay, suggesting that 11β-HSD2 is a cause of GC-resistance in ALL.

Original language	English
Pages (from-to)	1644-1648
Number of pages	5
Journal	Leukemia Research
Volume	35
Issue number	12
DOIs	https://doi.org/10.1016/j.leukres.2011.07.002
Publication status	Published - Dec 2011
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2011.07.002

Cite this

@article{86ca1865d8324c379b9544f2791b045a,

title = "Expression of 11beta-hydroxysteroid dehydrogenase 2 contributes to glucocorticoid resistance in lymphoblastic leukemia cells",

abstract = "Synthetic glucocorticoids (GCs) form a crucial first-line treatment for childhood acute lymphoblastic leukemia (ALL). However prolonged GC therapy frequently leads to GC-resistance with an unclear molecular mechanism. 11β-hydroxysteroid dehydrogenase (11β-HSD) 2 inactivates GCs within cells. Here, we show the association between GC sensitivity and 11β-HSD2 expression in human T-cell leukemic cell lines. 11β-HSD2 mRNA and protein levels were considerably higher in GC-resistant MOLT4F cells than in GC-sensitive CCRF-CEM cells. The 11β-HSD inhibitor, carbenoxolone pre-treatment resulted in greater cell death with prednisolone assessed by methyl-thiazol-tetrazolium assay and caspase-3/7 assay, suggesting that 11β-HSD2 is a cause of GC-resistance in ALL.",

keywords = "11β-Hydroxysteroid dehydrogenase 2, Acute lymphoblastic leukemia, Glucocorticoid resistance",

author = "Shuji Sai and Yuichi Nakagawa and Rie Yamaguchi and Masako Suzuki and Kimiyoshi Sakaguchi and Shuichi Okada and Seckl, {Jonathan R.} and Takehiko Ohzeki and Chapman, {Karen E.}",

year = "2011",

month = dec,

doi = "10.1016/j.leukres.2011.07.002",

language = "English",

volume = "35",

pages = "1644--1648",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier",

number = "12",

}

TY - JOUR

T1 - Expression of 11beta-hydroxysteroid dehydrogenase 2 contributes to glucocorticoid resistance in lymphoblastic leukemia cells

AU - Sai, Shuji

AU - Nakagawa, Yuichi

AU - Yamaguchi, Rie

AU - Suzuki, Masako

AU - Sakaguchi, Kimiyoshi

AU - Okada, Shuichi

AU - Seckl, Jonathan R.

AU - Ohzeki, Takehiko

AU - Chapman, Karen E.

PY - 2011/12

Y1 - 2011/12

N2 - Synthetic glucocorticoids (GCs) form a crucial first-line treatment for childhood acute lymphoblastic leukemia (ALL). However prolonged GC therapy frequently leads to GC-resistance with an unclear molecular mechanism. 11β-hydroxysteroid dehydrogenase (11β-HSD) 2 inactivates GCs within cells. Here, we show the association between GC sensitivity and 11β-HSD2 expression in human T-cell leukemic cell lines. 11β-HSD2 mRNA and protein levels were considerably higher in GC-resistant MOLT4F cells than in GC-sensitive CCRF-CEM cells. The 11β-HSD inhibitor, carbenoxolone pre-treatment resulted in greater cell death with prednisolone assessed by methyl-thiazol-tetrazolium assay and caspase-3/7 assay, suggesting that 11β-HSD2 is a cause of GC-resistance in ALL.

AB - Synthetic glucocorticoids (GCs) form a crucial first-line treatment for childhood acute lymphoblastic leukemia (ALL). However prolonged GC therapy frequently leads to GC-resistance with an unclear molecular mechanism. 11β-hydroxysteroid dehydrogenase (11β-HSD) 2 inactivates GCs within cells. Here, we show the association between GC sensitivity and 11β-HSD2 expression in human T-cell leukemic cell lines. 11β-HSD2 mRNA and protein levels were considerably higher in GC-resistant MOLT4F cells than in GC-sensitive CCRF-CEM cells. The 11β-HSD inhibitor, carbenoxolone pre-treatment resulted in greater cell death with prednisolone assessed by methyl-thiazol-tetrazolium assay and caspase-3/7 assay, suggesting that 11β-HSD2 is a cause of GC-resistance in ALL.

KW - 11β-Hydroxysteroid dehydrogenase 2

KW - Acute lymphoblastic leukemia

KW - Glucocorticoid resistance

UR - http://www.scopus.com/inward/record.url?scp=80055115992&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.07.002

DO - 10.1016/j.leukres.2011.07.002

M3 - Article

C2 - 21794917

AN - SCOPUS:80055115992

SN - 0145-2126

VL - 35

SP - 1644

EP - 1648

JO - Leukemia Research

JF - Leukemia Research

IS - 12

ER -

Expression of 11beta-hydroxysteroid dehydrogenase 2 contributes to glucocorticoid resistance in lymphoblastic leukemia cells

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this